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Background: In 2008, artemether - lumefantrine (AL) and dihydroartemisinin - piperaquine (DHAP) were added to
artesunate - amodiaquine (AS-AQ) as first-line drugs for uncomplicated malaria in Ghana. The introduction of new
drugs calls for continuous monitoring of these drugs to provide timely information on trends of their efficacy and
safety to enhance timely evidence-based decision making by the National Malaria Control Programme. In this
regard, the therapeutic efficacy of AL was monitored from September 2010 to April 2011 in four sentinel sites
representing the three main ecological zones of the country.
Methods: The study was a one-arm prospective evaluation of clinical and parasitological responses to directly
observed treatment for uncomplicated malaria among children aged 6 months to 59 months using the 2009
WHO protocol for surveillance of anti-malarial drug efficacy. Children recruited into the study received weight-based
20/120 mg AL at 0, 8, 24, 36, 48, and 60 hrs. Parasitaemia levels were assessed on days 2, 3, 7, 14, 21, 28, and at any
time a study child was brought to the clinic with fever.
Results: A total of 175 children were enrolled into the study: 56 in the savanna zone, 78 in the forest zone and 41
in the coastal zone. Per-protocol analysis showed that the overall PCR-corrected cure rates on day 14 and day 28
were 96.5% (95% CI: 92.1, 98.6) and 95.4% (95% CI: 90.3, 98.0), respectively, with statistically significant differences
between the ecological zones. The 90.4% day-28 cure rate observed in the savannah zone (95% CI: 78.2, 96.4) was
significantly the lowest compared with 100% (95% CI: 93.2, 99.9) in the forest zone and 93.8% (95% CI: 77.8, 98.9) in
the coastal zone (P = 0.017). Fever and parasite clearance were slower among children enrolled in the savannah
zone. Gametocytaemia after day-3 post-treatment was rare in all the zones.
Conclusions: The study has shown that AL remains efficacious in Ghana with significant ecologic zonal differences.
The savannah zone may be a potential zone for any emergence of resistant alleles as a result of the slower parasite
clearance observed in the zone.
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Malaria remains one of the major causes of morbidity
and mortality worldwide. It is estimated that in 2010
there were approximately 216 million cases of malaria
worldwide, of which 81% were in Africa. In the same
year, malaria accounted for approximately 655,000
deaths worldwide, of which 91% were in Africa [1]. In
2010, malaria was estimated to account for 38.2% of all
out patient attendance; 34.9% of all admissions; and
33.7% of under-five mortality in Ghana [2].
The current control strategy in Ghana has case man-
agement based on prompt recognition and adequate
treatment as its main focus. Chloroquine had been the
first-line drug for the treatment of uncomplicated mal-
aria in Ghana for decades until 2001, when results from
studies conducted in six sentinel sites (between 1998
and 2001) showed treatment failure rates of between
8.6% and 26.8% [3]. At a consensus-building workshop
in August 2003, Ghana decided to change her anti-
malarial drug policy based on the evidence provided by
the 2001 studies, among others. The focus of treatment
options was the use of artemisinin-based combination
therapy (ACT) to slow down the spread of drug resist-
ance. This was recommended because of the rapid effect
on fever and parasite clearance as well as a reduction in
gametocyte carriage rates [4,5]. In January 2005, Ghana
adopted the artesunate-amodiaquine (AS-AQ) combin-
ation as the first-line drug for the treatment of uncom-
plicated malaria [6]. Artemether-lumefantrine (AL) and
dihydroartemisinin-piperaquine (DHAP) were added to
AS-AQ as first-line drugs for uncomplicated malaria in
Ghana in 2008 [7].
The introduction of new drugs calls for continuous
monitoring of these drugs to provide timely information
on trends of their efficacy and safety to enhance timely
evidence-based decision making by the National Malaria
Control Programme (NMCP). In this regard, a surveil-
lance system, coordinated by the Noguchi Memorial In-
stitute for Medical Research (NMIMR), was established
in 2005 to provide data on first-line anti-malarial drugs
from 10 sentinel sites across the country. This paper
covers the therapeutic efficacy of AL across three eco-
logical zones in Ghana during the period September
2010 to April 2011 using the 2009 WHO protocol for
surveillance of anti-malarial drug efficacy [8].
Methods
Study sites
The AL study was conducted in four of the 10 sentinel
sites representing the three main ecological zones of
Ghana. These were Navrongo War Memorial Hospital in
the savannah zone; Bekwai Municipal Hospital and
Begoro Government Hospital in the forest zone; and
Ewim Health Centre in the coastal zone.The Navrongo War Memorial Hospital is located in
the Kassena Nakana East district in the Upper East re-
gion of Ghana. The Kassena Nankana East district has
an estimated population of 109,944 with an annual aver-
age rainfall of 950 mm. Malaria in the district is peren-
nial with marked seasonal variation. The peak
transmission season coincides with the major rains be-
tween June and October. The Bekwai Municipal Hos-
pital is located in the Bekwai Municipality in the
Ashanti region of Ghana. The Bekwai Municipality has
an estimated population of 118,024. Annual rainfall in
the municipality is 1,600 – 1,800 mm with double max-
ima rainfall in May and October each year. Malaria
transmission in the Municipality is intense and peren-
nial. The Begoro Government Hospital is located in the
Fanteakwa district in the Eastern region of Ghana. The
Fanteakwa district has an estimated population of
108,614. Annual rainfall in the district is 150 –
2,000 mm with double maxima rainfall in June and
October each year. Malaria transmission in the district is
intense and perennial. The Ewim Health Centre is
located within the Cape-Coast Metropolis in the Central
region of Ghana. The Cape-Coast metropolis has an esti-
mated population of 169,894. Annual rainfall in the me-
tropolis is 750 – 1,000 mm with double maxima rainfall
in June and December each year. Malaria transmission
in the metropolis is perennial [9-13].
Study population
The study population involved all children aged between
six and 59 months presenting at the Out-Patient Depart-
ment (OPD) of a study site clinic with symptoms sug-
gestive of malaria. Once a clinical diagnosis of malaria
was made by the study Nurse, samples of blood were
obtained from a finger prick to prepare thick and thin
smears for malaria microscopy and haemoglobin level
determination. Children meeting the inclusion criteria
were recruited into the study and followed up for a
minimum of 14 days and a maximum of 28 days. Briefly,
the inclusion criteria included axillary temperature ≥
37.5°C or history of fever during the past 24 hrs; mono-
infection with Plasmodium falciparum; parasite count
ranging between 1,000 and 250,000 per μl; haemoglobin
level > 5 g/dl; absence of signs/symptoms of severe mal-
aria; and parent’s willingness to give their consent.
Children recruited into the study received weight-
based 20/120 mg AL (CoartemW – batch number x1435
supplied by WHO, Geneva) at 0, 8, 24, 36, 48, and
60 hrs. All treatments were given under direct observa-
tion by a study nurse and children were observed for
30 minutes to ascertain retention of medicine. Children
who vomited during the observation period were re-
treated with the same dose of medicine and observed for
an additional 30 minutes. Children with repeated
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per national standard treatment guidelines and excluded
from the study. All children were allowed use of anti-
pyretics. Children who showed signs/symptoms of severe
malaria, had serious adverse events or required blood
transfusion were withdrawn from the study.
Outpatient follow-up visits were scheduled for days 1,
2, 3, 7, 14, 21, and 28 after treatment (day of treatment
was counted as day-0). At each visit to the clinic, chil-
dren were examined physically and information on
symptoms, axillary temperature, and respiratory rate
recorded on a Case Record Form (CRF). Parasitaemia
levels (asexual and sexual) were assessed on days 2, 3, 7,
14, 21, 28, and any day within the 28-day follow-up
period that a child is brought to the clinic with fever.
Thick and thin smears were stained with 3% Giemsa for
30–45 minutes for quantification of asexual parasites
against 200 white blood cells using a hand tally counter.
Sexual parasite counts were done per 1,000 white blood
cells. Parasitaemia levels were expressed per μl blood as-
suming white blood cell count of 8,000 per μl blood. A
smear was declared negative when examination of 100
thick-film fields did not show presence of asexual para-
sites. For quality control purposes, all blood slides were
read by two qualified independent microscopists, and
discordant readings were re-examined by a third quali-
fied independent microscopist. Discordance was defined
as differences between the first and second microsco-
pists regarding presence/absence of asexual or sexual
parasites; species diagnosis; and day-0 counts meeting
the inclusion criterion of 1,000 – 250,000 per μl blood.
The first or second reading was taken as final depending
on whichever agrees with the third reading. Filter paper
blots were obtained on day-0 and at recurrence of para-
sitaemia for PCR genotyping, and merozoite surface pro-
teins 1 and 2 (msp1, msp2), and glutamate-rich protein
(glurp) used to distinguish between re-infection and re-
crudescence. Haemoglobin levels were assessed for all
study children on days 0, 14, and 28.
Data analysis
Per protocol analysis was applied in this study. Primary
outcomes were treatment outcomes on day-14 and day-Table 1 Demographic, clinical, parasitological, and haematolo
Characteristic Total (N = 175)
Savan
Male/Female 85/90
Median age in months (range) 32 (6 – 59) 35 (9
Mean axillary temperature in°C (95% CI) 38.0 (37.5, 38.4) 38.0 (3
GM Parasite count/μl a (range) 35009 (1240, 233608) 22775 (1
Mean Haemoglobin level in g/dl (95% CI) 10.0 (9.2, 10.7) 9.4 (8
a Geometric mean parasite count.28 for the different ecological zones based on the WHO
2009 criteria: Early treatment failure (ETF), Late Para-
sitological Failure (LPF), Late Clinical Failure (LCF), and
Adequate Clinical and Parasitological Response (ACPR)
[8]. Secondary outcomes were patterns of fever and
parasite clearance assessed for the different ecological
zones using proportions (with 95% CI) of children fe-
brile/with temperature ≥ 37.5°C or parasitaemic within
the follow-up period. Haematological responses were
also assessed using mean haemoglobin levels on day-14
and day-28. Proportions were compared using chi-
square and Fisher’s exact tests. Normally distributed
variables were compared using Student’s t-test while
skewed distributions such as parasite counts were log
transformed before using the normal approximation.
Differences were considered significant at p < 0.05.
Ethics
The Institutional Review Board of the Noguchi Memor-
ial Institute for Medical Research, University of Ghana,
reviewed and approved the study. Written informed
consent was obtained from each parent/guardian at the
start of the study. Each parent/guardian was informed of
the objectives, methods, anticipated benefits and poten-
tial hazards of the study. They were also informed that
they were at liberty to withdraw their children from the
study at any time without penalty.
Results
Baseline characteristics
Of the 360 children screened, 175 (48.6%) met the inclu-
sion criteria and were enrolled into the study: 56 in the
savannah zone, 78 in the forest zone, and 41 in the
coastal zone. Characteristics of patients at enrolment are
presented in Table 1. The mean axillary temperature was
significantly lowest among patients enrolled from the
coastal zone. The other baseline characteristics assessed
(i.e. male/female ratio, median age, geometric parasite
density, and mean haemoglobin levels) did not show any
significant difference between the ecological zones.
There were no reports of previous anti-malarial intake
prior to enrollment in all the three ecological zones. Out
of the 175 patients enrolled, a cumulative total of 169gical characteristics of patients on day of enrolment
Ecological zone p-value
nah n = 56 Forest n = 78 Coastal n = 41
30/26 39/39 16/25 0.346
– 55) 33 (6 – 59) 24 (7 – 59) 0.077
7.7, 38.2) 38.5 (38.3, 38.7) 37.0 (35.1, 38.9) 0.039
240, 198440) 40983 (1423, 197080) 46669 (6647, 233608) 0.115
.9, 9.9) 10.3 (8.7, 12.0) 10.1 (9.6, 10.5) 0.557












ETF 5 5 0 0
LCF 0 0 0 0
LPF 1 0 0 1
ACPR 163 51 75 37
NAa 6 0 3 3
Classification (Day 28)
ETF 5 5 0 0
LCF 5 2 0 3
LPF 10 2 3 5
ACPR 144 47 67 30
NAa 11 0 8 3
a Not assessed.
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day-28, respectively, giving a total of six patients who
were neither assessed on day-14 nor day-28. Three of
these patients were lost to follow-up by day-3; 1 was
withdrawn because of danger sign on day-1; 1 was with-
drawn because of danger sign on day-2; and 1 with-
drawn because of failure to complete treatment. The
day-1 danger sign (patient from the coastal zone) was
convulsion whilst the day-2 danger sign (patient from
the forest zone) was excessive vomiting. Both children
with danger signs were detained and given supportive
treatment until they recovered.
Primary outcomes
Out of 169 evaluable patients assessed on day-14, 163 or
96.5% (95% CI: 92.1, 98.6) showed an adequate clinical
and parasitological response. Five of the six treatment
failures were early treatment failures that occurred in
the savannah zone. The only late parasitological failureFigure 1 Day 28 pcr-corrected ACPR/Cure rate (including 95% CI) forobserved on day-14 occurred in the coastal zone and
was confirmed by PCR (Table 2).
For day-28 evaluable patients, 47 out of 56 or 83.9%
(95% CI: 71.2, 92.0) in the savannah zone; 67 out of 70
or 95.7% (95% CI: 87.2, 98.9) in the forest zone; and 30
out of 38 or 79% (95% CI: 62.2, 89.9) in the coastal zone
showed adequate clinical and parasitological response
(Table 2). Pcr-corrected outcomes on day-28 showed an
overall cure rate of 95.4% (95% CI: 90.3, 98.0). Cure rate
within the savannah zone was significantly the lowest
(90.4%; 95% CI: 78.2, 96.4) compared with 100% (95%
CI: 93.2, 99.9) in the forest zone and 93.8% (95% CI:
77.8, 98.9) in the coastal zone (p = 0.017) (Figure 1).
Secondary outcomes
Generally, proportion of children who were febrile dur-
ing the first follow-up week decreased with day within
the forest and coastal zones. Children in the two zones
remained afebrile on day-3 and day-7 post-treatment.
Although the proportion of febrile children in the
savannah zone significantly decreased from 100% on
day-0 to 1.8% (95% CI: 0.1, 10.8) on day-2, the pro-
portion increased to 18.2% (95% CI: 9.5, 31.4) on day-3
before decreasing again to 7.8% (95% CI: 2.5, 19.8) on
day-7. Febrile cases were, therefore, recorded on all days
within the first follow-up week in the savannah zone.
The proportion of children still febrile on day-1 post-
treatment was significantly higher in the savannah zone
(42.9%; 95% CI: 30.0, 56.7) compared with the forest
zone (16.7%; 95% CI: 9.5, 27.2) and the coastal zone
(10.5%; 95% CI: 3.4, 25.7) (p < 0.001) (Figure 2).
Regarding parasitaemia, all children within the forest
and coastal zones cleared their parasites by day-2 post-
treatment, and none of them was parasitaemic on day-3
and day-7. In the savannah zone, 8/55 or 14.5% (95% CI:
6.9, 27.2) were parasitaemic on day-2. However, no
child was parasitaemic on day-3 and day-7 (Figure 3).
A further analysis of the children who were parasitaemic
on day-2 showed that 5/8 (62.5%; 95% CI: 25.9,evaluable patients by ecological zone.
Figure 2 Proportion of patients with fever during first follow-up week by ecological zone.
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(Figure 4) and were thus classified as ETF as per proto-
col. All the children became aparasitaemic on day-3
without any rescue treatment to those classified as ETF
(Figure 4). Parasite recurrence was observed on day-21
in one of the eight children who were parasitaemic
on day-2.
At enrolment, gametocytaemia was prevalent only in
the savannah zone at a rate of 7.1% (4/56). By day-2
post-treatment, prevalence of gametocytaemia had
declined to 0% and remained so in the zone on days 3,
7, and 21. Days 14 and 28 in the savannah zone had only
1 child (1.8%) with gametocytes. Gametocytaemia wasFigure 3 Proportion of patients with parasites during first follow-up wabsent on all follow-up days among children enrolled in
the forest zone. For children enrolled in the coastal zone
gametocytaemia was prevalent on day-2 post-treatment
at a rate of 10.5% (4/38), halved by day-3 at a rate of
5.3% (2/38), declined to 0% by day-7, and remained same
throughout the remaining follow-up days (Figure 5).
There were no significant differences between mean
haemoglobin concentration assessed prior to treatment on
day-0 and mean haemoglobin concentration assessed on
day-14 and day-28 post-treatment among children in the
savannah and forest zones. For children in the coastal
zone, mean haemoglobin concentration significantly
increased from 10.1 g/dl (95% CI: 9.6, 10.5) on day-0 toeek by ecological zone.
Figure 4 Pattern of parasite clearance among children parasitaemic on day-2 in the Savannah zone.
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(Table 3).
Discussion
Following the inclusion of artemether - lumefantrine
combination as one of the first-line drugs for the treat-
ment of uncomplicated malaria in Ghana in 2008 [7],
there was the need to study its therapeutic efficacy in
four sentinel sites representing the three main ecological
zones of the country during the 2010/2011 surveillance
period.
The study has shown that the overall PCR-corrected
cure rate for Ghana is 95.4% (95% CI: 90.3, 98.0) with
the savannah zone showing a significantly lower rate of
90.4% (95% CI: 78.2, 96.4). The over 90% cure rate of AL
in Ghana is comparable with findings from other studies
in Africa within the past decade [5,14-20], and suggests
that Ghana as a whole has not reached the 10% cut-off
failure rate necessary for the review of AL as one of the
first line drugs in the treatment of uncomplicated mal-
aria in the country [8]. However, the 9.6% earlyFigure 5 Gametocyte carriage rate during the follow-up period by ectreatment failure rate observed in the savannah zone is
worrying and suggests the need for conduct of pharma-
cokinetic studies during subsequent efficacy studies to
determine the adequacy of plasma drug concentrations,
which is necessary for describing treatment failures [21].
Fever and parasite clearance were slower among chil-
dren enrolled in the savannah zone. Whereas no child
was febrile on day-3 and day-7 in the forest and coastal
zones, febrile cases were reported on all days among
children in the savannah zone during the first follow-up
week. The proportion of children still febrile on day-1
post-treatment was significantly highest in the savannah
zone (42.9%; 95% CI: 30.0, 56.7) compared with the for-
est zone (16.7%; 95% CI: 9.5, 27.2) and the coastal zone
(10.5%; 95% CI: 3.4, 25.7) (p < 0.001). Additionally, 8/55
or 14.5% (95% CI: 6.9, 27.2) of the children enrolled in
the savannah zone were parasitaemic on day-2 post-
treatment whilst no child was parasitaemic on the same
day in the forest and coastal zones. Out of the 8 parasi-
taemic children 5 (62.5%; 95% CI: 25.9, 89.8) had para-
site count greater than the day-0 count but remainedological zone.




Day 0 Mean Hb
(95% CI)
9.4 (8.9, 9.9) 10.3 (8.7, 12.0) 10.1 (9.6, 10.5)
Day 14 Mean Hb
(95% CI)
9.6 (9.2, 10.0) 10.0 (9.7, 10.3) 10.6 (10.2, 11.0)
Day 28 Mean Hb
(95% CI)
10.0 (9.6, 10.4) 10.6 (10.3, 10.9) 11.0 (10.6, 11.4)
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treatment without any rescue treatment. The rapid rise
in asexual parasitaemia after commencement of ACT
treatment has been reported in Nigeria and attributed to
a possible larger load of sequestered parasites in deep
tissues in some patients. In the Nigeria study, parasit-
aemia levels peaked at one hour after the first dose of
AL, and by 16 hours post-treatment all parasites had
been cleared among children with initial rise in parasit-
aemia [22]. In our study, total asexual parasite clearance
for children with increased parasitaemia on day-2 was
achieved on day-3. This observation, coupled with the
known phenomenon of parasite mobilization from
deep tissues by ACT raises concern about the WHO
criteria for ETF classification in relation to parasite
densities [23]. It may be worthwhile shifting the criteria
from day-2 to day-3 post-treatment in areas of intense
transmission. This notwithstanding, the delayed clearance
of fever and parasites in the savannah zone need to
be further studied taking into account the possible
effects of ACT usage on parasite dynamics within the
population [24].
Pre-treatment gametocytaemia was prevalent only in
the savannah zone (7.1%) and declined to 0% by day-2
post-treatment whilst gametocytaemia was prevalent
on day-2 post-treatment in the coastal zone (10.5%),
halved by day-3 (5.3%), and declined to 0% by day-7 post-
treatment. This finding suggests that ACT remains effi-
cacious in gametocyte clearance in Ghana. The efficacy in
gametocyte clearance has the advantage of potentially
slowing down the transmission of resistant alleles [25].
Post-treatment mean haemoglobin concentration was
significantly higher than pre-treatment concentration in
the coastal zone but not the forest and savannah zones.
This finding suggests that the therapeutic efficacy of AL
resulting from rapid parasite clearance may not neces-
sarily translate into significant post-treatment increases
in haemoglobin concentrations during a 28-day follow
up period. A couple of studies in Africa have reported
non-significant post-treatment increases in haemoglobin
concentrations with AL treatment during a 28-day fol-
low-up period of patients treated for acute uncompli-
cated malaria [15,26] whilst a couple of studies in Ghanahave reported significant increases during the same
follow-up period [5,27].
Conclusions
There is evidence to show that AL remains efficacious in
Ghana with significant ecologic zonal differences. The
savannah zone may be a potential zone for any emer-
gence of resistant alleles as a result of the slower parasite
clearance observed in the zone. Pharmacokinetic studies
will be useful in future anti-malarial drug resistance sur-
veillance activities in Ghana to better describe treatment
failures. Ghana’s policy of multiple first-line therapy is in
the right direction, and needs to be supported by all sta-
keholders as it delays the emergence and slows spread of
drug resistance [28,29]. Furthermore, the WHO criteria
for ETF may need to be reviewed following the observa-
tion that all 5 children classified as ETF on the basis of
parasite count on day-2 being greater than parasite
count on day-0 cleared all parasites on day-3, without
any rescue treatment, and remained aparasitaemic dur-
ing the follow-up period.
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